William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Morgan Stanley Remains a Hold on Genmab (GMAB)
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Fintel on MSN2d
William Blair Upgrades Genmab A (GMAB)
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
Market Inference2d
Key Focus for Genmab A/S Investors
Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward ...
Nordic Shares Decline; Genmab Falls Furthest
Stocks in the Nordic region declined Tuesday, with the OMX Nordic 40 Index declining 2.2%. Genmab A/S posted the largest decline among large stocks during the session, declining 9.2%, followed by ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Positive Report for Genmab (GMAB) from William Blair
Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Fierce Biotech4d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
J&J will not exercise worldwide license option for HexaBody-CD38, says Genmab
Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...
Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option
Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.